Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy

---

DEMİRCAN N. C., DANE F., Ozturk M. A., Babacan N. A., Besiroglu M., Kaya S., ...Daha Fazla

JOURNAL OF BUON, cilt.24, sa.4, ss.1494-1500, 2019 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 24 Sayı: 4
• Basım Tarihi: 2019
• Dergi Adı: JOURNAL OF BUON
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.1494-1500
• Anahtar Kelimeler: bevacizumab, colorectal cancer, prognostic factors, PRIMARY TUMOR RESECTION, K-RAS MUTATION, COLON-CANCER, CURATIVE RESECTION, PHASE-III, FOLLOW-UP, STAGE, CHEMOTHERAPY, OUTCOMES, TRIAL
• Marmara Üniversitesi Adresli: Evet

Özet

Purpose: Colorectal cancer (CRC) is a significant cause of cancer mortality worldwide. Survival has improved with bevacizumab in metastatic CRC treatment. Our purpose was to analyse survival and prognostic factors in metastatic CRC patients treated with first-line bevacizumab-based treatment.